AC Immune Reports Second Quarter 2018 Financial Results and Corporate Update

Wednesday, August 8, 2018 @ 12:30 pm

New total cash position of approximately CHF 210 million that is expected to extend cash runway to Q3 2021, excluding potential incoming milestones
Financial position strengthened after Q2 close due to issuance of new shares, raising gross proceeds of USD 117.5 million
Crenezumab: Phase 3 trial CREAD 2 fully recruited in July 2018; new Phase 2 data analysis provides strong evidence for principal target engagement of Abeta oligomers
Selection of small molecules targeting Tau (Tau Morphomers^TM) for clinical development in Alzheimer's disease

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced financial results for the second quarter and first half ended June 30, 2018.

Read the full media release below.

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

Cytosurge and Lexogen partner to advance live-cell sequencing

Cytosurge and Lexogen have partnered to advance live-cell sequencing (Live-seq) by integrating Cytosurge's FluidFM OMNIUM platform with Lexogen's LUTHOR HD kit. This collaboration enables the sequencing of cellular biopsies while preserving cell viability, offering a scalable and accessible workflow for dynamic transcriptomic studies. The combination of gentle cytoplasmic biopsy extraction with ul
October 15, 2024

BD and ten23 Health partner for aseptic manufacturing

The innovative RFID-based solution for prefilled syringes (PFS) aims to boost efficiency and enhance traceability during the fill-and-finish process and product distribution
October 7, 2024

Alithea Genomics secures loan from Swiss Technology Fund

Alithea Genomics, a leader in large-scale RNA sequencing, received a loan guarantee from Switzerland's Technology Fund, aiding its growth. The fund, part of the Swiss Federal Office for the Environment, supports companies reducing greenhouse gas emissions. Alithea's innovative technologies, such as BRB-seq and DRUG-seq, cut costs, time, and resource use in RNA sequencing, promoting sustainability.
September 24, 2024

Swiss innovators champion industrial biotech: Focus on flexibility, market diversity, and environmental impact

Industrial biotechnology promotes more energy-efficient and sustainable manufacturing processes as well as creating opportunities for reducing pollution, reusing waste and creating new products. It underpins a circular economy and a more sustainable chemicals industry which prioritizes protecting scarce natural resources. New bio-based products and processes have far-reaching and disruptive impact
September 24, 2024

Mabylon receives over CHF 1.3 million research grants from Innosuisse, Target ALS and ALS Association

Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has received three grants totaling more than CHF 1.3 million from Innosuisse Swiss Innovation Agency, Target ALS and the ALS Association.
September 24, 2024